Torrent Pharmaceuticals TORNTPHARM
Chronic-focused branded formulations (cardiac, CNS, GI, diabetes) in India, Brazil and Germany; absorbed J B Chemicals in 2026
Mapped in 1 theme: Pharmaceuticals.
Where Torrent Pharmaceuticals sits in the supply chain
Torrent Pharmaceuticals appears in 1 supply-chain layer in one theme, Pharmaceuticals.
Pharmaceuticals › India branded formulations
OperatorOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 10,728 | 11,516 | 13,980 |
| Net profit | 1,656 | 1,911 | 2,138 |
Latest-year revenue ₹13,980 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Among the most productive Indian field forces, with ~55%+ of revenue from India branded formulations
- J B Chemicals (Cilacar, Rantac, Metrogyl and ex-Sanofi/Novartis brands) consolidated from Jan 2026 and amalgamated in Jul 2026 - India revenue rose 43% YoY in Q4 FY26
- Track record of buying and re-energising brands (Elder, Unichem India, Curatio)
Risks
- Rich valuation leaves little room for integration slips
- Acquisition and exceptional charges cut Q4 FY26 profit 27% YoY
- Small US business with past USFDA issues at Indrad and Dahej
Common questions
What does Torrent Pharmaceuticals do?
Chronic-focused branded formulations (cardiac, CNS, GI, diabetes) in India, Brazil and Germany; absorbed J B Chemicals in 2026.
Where does Torrent Pharmaceuticals sit in the supply chain?
Torrent Pharmaceuticals (NSE: TORNTPHARM) is mapped in 1 supply-chain layer: India branded formulations (Pharmaceuticals).
Who are Torrent Pharmaceuticals' peers?
In the India branded formulations layer of Pharmaceuticals: Sun Pharmaceutical Industries, Mankind Pharma, Alkem Laboratories, Abbott India, Eris Lifesciences, Cipla and 4 more.
What is Torrent Pharmaceuticals' market cap and valuation?
As of 30 Oct 2026: market cap ₹1.76L Cr, P/E 81.1x, ROCE 15.2%, ROE 27.4%, dividend yield 0.82%.